Patent ID: 6531476
Filing Date: 2003-03-11
Classification: A61P,C07D

Abstract:
A method for inhibiting the replication of human immunodeficiency virus (HIV), comprising administering to an individual in need of such a teatment an inhibitory effective amount of a piperazine derivative corresponding to the general formula (I): in which:A and B represent, independently of each other, a C&boxH;O, C&boxH;S or CR7R8 group in which R7 represents a hydrogen atom or a group chosen from methyl, cyano, cyanomethyl, CO2CH3 and (C&boxH;O)CH3 groups, while R8 represents a hydrogen atom or a phenyl group; R1, R2, R3, R4, R5 and R6 represent, independently of each other, a hydrogen atom, a hydroxyl group or a linear or branched C1-C5 alkoxy group; X represents: either a group chosen from C&boxH;O, O(C&boxH;O), O(C&boxH;S), O(SO2), NH(C&boxH;O), NH(C&boxH;S), NH(SO2), S(C&boxH;O) and S(C&boxH;S) groups, in which case Y represents either a group NR9R10 or CR9R10R11 in which R9, R10 and R11 represent, independently of each other, a hydrogen atom, a linear or branched C1 to C5 alkyl, C2 to C5 alkenyl or C2 to C5 alkynyl group, or Y represents a nitrogen heterocycle selected from the group consisting of pyrollidino and piperidino; or an oxygen or sulfur atom or a group chosen from O(C&boxH;O)O, NH(C&boxH;O)O and S(C&boxH;O)O groups, in which case Y represents a group CR9R10R11 in which R9, R10 and R11 have the same meaning as above; or a pharmaceutically acceptable salt thereof.